Table 3.
Efficacy of PegIFNα/RBV for 4 weeks + 200 mg boceprevir TID plus PegIFNα/RBV for 44 weeks.
| Cirrhosis | Prior treatment a | SVR24 rate in GT-1 | Study and trial phase | Ref. |
|---|---|---|---|---|
| No cirrhosis |
Naïve | 76.3% (74/97) | SPRINT-1, phase 2 | Kwo et al., 2010 |
| Naïve | 67.4% (223/331) | SPRINT-2, phase 2 | Poordad et al., 2011 | |
| Experienced | 66.4% (85/128) | RESPOND-2, phase 3 | Bacon et al., 2011 | |
| Naïve | 59.2% (87/147) | HCV-TARGET, phase 3 | Sterling et al., 2015 | |
| Experienced | 41.7% (68/163) | |||
| Null response | 40.8% (20/49) | PROVIDE, phase 3 | Vierling et al., 2014 | |
| Partial response | 67% (57/85) | |||
| Relapse | 96.4% (27/28) | |||
| Naïve | 64.1% (387/604) | Protocol 6086, phase 3 | Poordad et al., 2013 | |
| Non-response | 47.2% (17/36) | P05685AM2, phase 3 |
Flamm et al., 2013 |
|
| Relapse | 70.4% (69/98) | |||
| Cirrhosis | Naïve | 41.7% (10/24) | SPRINT-2, phase 2 | Poordad et al., 2011 |
| Naïve | 50% (3/6) | SPRINT-1, phase 2 | Kwo et al., 2010 | |
| Naïve | 55% (33/60) | Protocol 6086, phase 3 | Poordad et al., 2013 | |
| Naïve | 32% (16/50) | HCV-TARGET, phase 3 | Sterling et al., 2015 | |
| Experienced | 31.1% (28/90) | |||
| Relapse | 53.9% (55/102) b | ANRS CO20, phase 3 | Hezode et al., 2014 | |
| Partial response | 38.3% (36/94) b | |||
| Null response | 0% (0/10) b | |||
| Experienced | 77.3% (17/22) | RESPOND-2, phase 3 | Bacon et al., 2011 | |
a
Naïve: patients were treatment-naïve prior to therapies in clinical trials. Experienced: patients experienced other HCV therapies prior to therapies in clinical trials.
b
SVR12 rates were evaluated in the study.